StockData
Acadia Pharmaceuticals Inc logo

Acadia Pharmaceuticals Inc (ACAD) stock

ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3027% below fair value
$18.32−0.35 (-1.87%)

Close on Nov 17, 2026Market cap $3.16BP/E 8.3Yield –

Acadia Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Acadia Pharmaceuticals's price to sales ratio was 2.8× on Nov 11, 2026, against 4.0× a year earlier. Over the last 5 years it ranged from 2.5× to 9.1×, with a median of 4.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.8×−1.5
2025Dec 31, 20254.3×+1.0
2024Dec 31, 20243.3×−4.8
2023Dec 29, 20238.1×+3.1
2022Dec 30, 20225.0×−2.9
2021Dec 31, 20217.9×−12.4
2020Dec 31, 202020.3×−1.6
2019Dec 31, 201921.9×+12.1
2018Dec 31, 20189.7×−29.9
2017Dec 29, 201739.6×−361.7
2013Oct 31, 2013401.3×+349.8
2012Dec 31, 201251.4×+49.9
2011Dec 30, 20111.5×−5.5
2010Dec 31, 20107.0×–

More Acadia Pharmaceuticals figures

See a number that looks wrong?